购物车
- 全部删除
您的购物车当前为空
常见问题解答
Kallikrein 5/KLK5 Protein, Mouse, Recombinant (His)
产品编号 TMPK-01158
The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches.
Kallikrein 5/KLK5 Protein, Mouse, Recombinant (His)
产品编号 TMPK-01158
The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches.
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 100 μg | ¥ 2,660 | 现货 | |
| 500 μg | ¥ 10,600 | 5日内发货 | |
| 1 mg | ¥ 17,800 | 5日内发货 |
大包装 & 定制
加入购物车
产品信息
| 生物活性 | Activity has not been tested. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
| 产品描述 | The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches. |
| 种属 | Mouse |
| 表达系统 | HEK293 Cells |
| 标签 | C-His |
| 蛋白编号 | Q9D140 |
| 别名 | SCTE,Klnc,KLK-L2,KLKL2,KLK5,Kallikrein c |
| 蛋白构建 | Gly30-Asn293 |
| 蛋白纯度 | > 95% as determined by Tris-Bis PAGE; > 95% as determined by HPLC |
| 分子量 | 29.9 kDa (predicted). Due to glycosylation, the protein migrates to 40-50 kDa based on Tris-Bis PAGE result. |
| 内毒素 | < 1 EU/μg by the LAL method. |
| 缓冲液 | Lyophilized from a solution filtered through a 0.22 μm filter, containing 20 mM NaAc, 150 mM NaCl (pH 5.0). Typically, 8% trehalose is incorporated as a protective agent before lyophilization. |
| 复溶方法 | Reconstitute the lyophilized protein in 20mM NaAc, 150mM NaCl (pH 5.0). The product concentration should not be less than 100 μg/ml. Before opening, centrifuge the tube to collect powder at the bottom. After adding the reconstitution buffer, avoid vortexing or pipetting for mixing. |
| 存储 | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
| 运输方式 | In general, Lyophilized powders are shipping with blue ice. |
| 研究背景 | The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches. |
计算器
技术支持
请阅读 重组蛋白用户指南 了解更多具体信息.
预览
嗨！很高兴为您提供帮助！
